Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced histologically confirmed well differentiated pancreatic neuroendocrine tumor~* Progressive disease within the last 12 months~* Measurable disease per RECIST Version 1.0 determined by multiphase MRI or triphasic CT~Exclusion Criteria:~* Prior treatment with mTOR or PI3K inhibitors~* Patients with more than 2 prior systemic treatment regimens~* Previous cytotoxic chemotherapy, targeted therapy, or biotherapy within the last 4 weeks~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BEZ235 (Type: EXPERIMENTAL): Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)
- Everolimus (Type: ACTIVE_COMPARATOR): Patients received Everolimus 10 mg qd p.o. (by mouth, daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).